PT  - JOURNAL ARTICLE
AU  - Andrejko, Kristin L.
AU  - Pry, Jake
AU  - Myers, Jennifer F.
AU  - Mehrotra, Megha
AU  - Lamba, Katherine
AU  - Lim, Esther
AU  - Fukui, Nozomi
AU  - DeGuzman, Jennifer L.
AU  - Openshaw, John
AU  - Watt, James
AU  - Jain, Seema
AU  - Lewnard, Joseph A.
AU  - ,
TI  - Waning of two-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection is robust to depletion-of-susceptibles bias
AID  - 10.1101/2022.06.03.22275958
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.03.22275958
4099  - http://medrxiv.org/content/early/2022/06/03/2022.06.03.22275958.short
4100  - http://medrxiv.org/content/early/2022/06/03/2022.06.03.22275958.full
AB  - Concerns about the duration of protection conferred by COVID-19 vaccines have arisen in postlicensure evaluations. However, “depletion of susceptibles” bias driven by differential accrual of infection among vaccinated and unvaccinated individuals may contribute to the appearance of waning vaccine effectiveness (VE) in epidemiologic studies, potentially hindering interpretation of estimates. We enrolled California residents who received molecular SARS-CoV-2 tests in a matched, test-negative design case-control study to estimate VE of mRNA-based COVID-19 vaccines between 23 February and 5 December 2021. We analyzed waning protection following 2 vaccine doses using conditional logistic regression models. Additionally, we used data from case-based surveillance along with estimated case-to-infection ratios from a population-based serological study to quantify the potential contribution of the “depletion-of-susceptibles” bias to time-varying VE estimates for 2 doses. We also estimated VE for 3 doses relative to 0 doses and 2 doses, by time since second dose receipt. Pooled VE of BNT162b2 and mRNA-1273 against symptomatic SARS-CoV-2 infection was 91.3% (95% confidence interval: 83.8-95.4%) at 14 days after second-dose receipt and declined to 50.8% (31.2-75.6%) at 7 months. Accounting for differential depletion-of-susceptibles among vaccinated and unvaccinated individuals, we estimated VE was 53.2% (23.6-71.2%) at 7 months among individuals who had completed the primary series (2 doses). With receipt of a third dose of BN162b2 or mRNA-1273, VE increased to 95.0% (82.8-98.6%), compared with zero doses. These findings confirm that observed waning of protection is not attributable to epidemiologic bias and support ongoing efforts to administer additional vaccine doses to mitigate burden of COVID-19.Competing Interest StatementJAL discloses receipt of grants and honoraria from Pfizer, Inc. unrelated to this work. Funding StatementThe study was supported by the California Department of Public Health. JP, JO, and JFM were supported by a grant from the ELC program of the US CDC (program number 0187.0150). JAL was supported by NIH/NIAID (grant R01-AI14812701)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the State of California, Health and Human Services Agency, Committee for the Protection of Human Subjects (Project Number: 2021-034).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDirect data requests to the corresponding author at kristin_andrejko{at}berkeley.edu CIConfidence Interval